MORE►
U.S. Food and Drug Administration
Drs. Seth Hays, Robert Rennaker and Michael Kilgard are recipients of the 2024 Cerami Award. [Photo: The University of Texas at Dallas]
3 UT Dallas Professors Win 2024 Cerami Award for Bioelectronic Medicine Research
by Lance Murray | Feb 6, 2025
The honors to UTD's Michael Kilgard, PhD, Robert Rennaker, PhD, and Seth Hays, PhD, are the first time the award will go to scientists who have made significant strides in translational bioelectronic medicine research.
by Lance Murray |
Nov 6, 2024
Caris said MI Cancer Seek will be used as a companion diagnostic to identify cancer patients who may benefit from treatment with targeted therapies.
MORE►
by Lance Murray |
Aug 12, 2024
MDIC is piloting the AMCH program, with support from the U.S. Food and Drug Administration, to help encourage the medical device industry to adopt advanced technology not just during device production but across the total product life cycle.
MORE►
by Lance Murray |
Oct 26, 2023
Revolution—which is based in Little Rock with corporate offices in Flower Mound and a manufacturing facility in Mesquite—says the introduction of clear food grade LLDPE PCR "will boost innovations in recycled packaging."
MORE►
Reata CEO Warren Huff [DI; Source photo: Reata]
Plano’s Reata Pharmaceuticals Launches First Product: The Rare-Disease Drug Skylarys
by David Seeley | Jun 29, 2023
Reata cleared the final FDA hurdle to get its rare-disease drug Skylarys on the market, the company announced Tuesday. The drug is now available to U.S. patients who've been diagnosed with Friedreich’s ataxia—a genetic disorder that can cause progressive damage to the nervous system. The announcement marks Reata’s first drug approval since the company was founded in 2002, according to the Dallas Morning News.
MORE►
by Lance Murray |
Mar 2, 2023
The FDA approval is not only a first for Reata's treatment of ultra-rare disease Friedreich's Ataxia. It's a first in the company's history, reports FiercePharma. On the news, Reata’s stock skyrocketed nearly 200% Wednesday, according to the Dallas Morning News, which cited an estimate that the drug will create a revenue stream in excess of $1 billion.
MORE►
by Lance Murray |
Jan 11, 2023
Nanoscope Therapeutics Inc., a Dallas-based clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, has appointed Massoud Motamed, Ph.D., as vice president of quality.
Motamed brings nearly a decade of CGMP quality and compliance experience, including extensive experience in manufacturing and regulatory review of gene therapy products....
MORE►
by Kevin Cummings |
Apr 18, 2022
Frisco-based InspectIR received the FDA emergency use authorization on Friday for its breathalyzer test, which tests for organic compounds associated with COVID-19 in a person's breath. According to a study, the tests are more effective than the rapid antigen tests available for free from the U.S. government.
MORE►
[Photo: via NatChittamai/iStockphoto]
Discovery: UTA Team Creating Water Modeling Tool for Trinity River; UTSW Finds How ‘Bad Cholesterol’ Enters Artery Walls
by Lance Murray | May 3, 2019
You'll also find out about how the FDA has granted Breakthrough Device status to a new Caris Life Sciences cancer test in this roundup of research and development activity in North Texas.
MORE►
